DiscoveryProbe™ Kinase Inhibitor Library
Catalog No.
L1024
A unique collection of 796 kinase inhibitors for high throughput screening (HTS) and high content screening (HCS).
Featured Products
- 1. Carly R Cabel, Briana A Guzman, et al. "Cell-based high-content approach for SARS-CoV-2 neutralization identifies unique monoclonal antibodies and PI3K pathway inhibitors." bioRxiv. 2024 Oct 7:2024.10.04.616743 PMID: 39416139
- 2. Carly R Cabel. "Identification and Characterization of CLK3 in the Colonic Epithelium as a Regulator of the Wnt Pathway." The University of Arizona ProQuest Dissertations & Theses, 2023. 30636192.
- 3. Haiyan An, Karen T. Elvers, et al. "A toolkit for the identification of NEAT1 2/paraspeckle modulators." Nucleic Acids Res. 2022 Nov 11;50(20):e119. PMID: 36099417
- 4. Volpatti JR, Endo Y, et al. "Identification of drug modifiers for RYR1-related myopathy using a multi-species discovery pipeline." Elife. 2020 Mar 30;9:e52946. PMID: 32223895
- 5. Croft CL, Cruz PE, et al. "rAAV-based brain slice culture models of Alzheimer's and Parkinson's disease inclusion pathologies." J Exp Med. 2019 Mar 4;216(3):539-555. PMID: 30770411
| Catalog No. | Product Name | Summary | Targets | CAS Number | Smiles |
| A3214 | AZD1152 | Aurora B kinase inhibitor,highly potent and selective | Aurora Kinase | 722543-31-9 | CCN(CCCOC1=CC2=C(C=C1)C(=NC=N2)NC3=NNC(=C3)CC(=O)NC4=CC(=CC=C4)F)CCOP(=O)(O)O |
| A3576 | LY2874455 | FGF/FGFR Inhibitor | FGFR | 1254473-64-7 | CC(C1=C(C=NC=C1Cl)Cl)OC2=CC3=C(C=C2)NN=C3C=CC4=CN(N=C4)CCO |
| A3781 | Ruxolitinib phosphate | JAK1/JAK2 inhibitor | JAK | 1092939-17-7 | [HH].C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3.OOP(=O)=O |
| A8180 | KN-62 | CaM kinase II inhibitor | P2X purinergic receptor | 127191-97-3 | CN(C(CC1=CC=C(C=C1)OS(=O)(=O)C2=CC=CC3=C2C=CN=C3)C(=O)N4CCN(CC4)C5=CC=CC=C5)S(=O)(=O)C6=CC=CC7=C6C=CN=C7 |
| A8336 | KU-60019 | ATM kinase inhibitor,potent and selective | ATM/ATR | 925701-49-1 | CC1CN(CC(O1)C)CC(=O)NC2=CC3=C(C=C2)SC4=C(C=CC=C4C3)C5=CC(=O)C=C(O5)N6CCOCC6 |
| B2190 | H 89 2HCl | Potent PKA inhibitor | PKA | 130964-39-5 | O=S(C1=CC=CC2=C1C=CN=C2)(NCCNC/C=C/C3=CC=C(Br)C=C3)=O.Cl.Cl |
| B4877 | URMC-099 | MLK3 inhibitor, orally bioavailable and brain penetrant | Others | 1229582-33-5 | CN1CCN(CC1)CC2=CC=C(C=C2)C3=CN=C4C(=C3)C(=CN4)C5=CC6=C(C=C5)NC=C6 |
| N1841 | Quercetin | Antitumor agent | NPI3K | 117-39-5 | C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O |
Related Biological Data
Related Biological Data
Related Biological Data
Related Biological Data
Related Biological Data
Related Biological Data
Related Biological Data
| Form | Pre-dissolved DMSO solutions | Stability | Solution: -20°C for 12 months, -80°C for 24 months |
| Packaging | 96-well rack with Matrix 2D Barcoded ScrewTop Storage tubes (250 μL or 100 μL/well, 10 mM DMSO). 96-well DeepWell format with peelable foil seal and EVA cap (100 μL/well, 10 mM DMSO). |
||
| Shipping Condition | Evaluation sample solution: ship with blue ice All other available size: ship with RT, or blue ice upon request |
||
-- Available in stock with overnight delivery and free shipping over $500.
-- Cost-effective and competitive price to save your budget.
-- Potent, selective and cell-permeable in inhibiting or activating target molecules.
-- Diverse in chemical structure and route of administration (oral/i.m/i.v injection etc.)
-- Detailed files describing potency, selectivity and applications etc.
-- Supported by published data from top peer-reviewed journals.
-- Guaranteed high quality with NMR and HPLC validation.
